Back to Search Start Over

Efficacy and safety of mesenchymal stem cells treatment for multidrug-resistant graft--host disease after haploidentical allogeneic hematopoietic stem cell transplantation

Authors :
Meng-Zhu Shen
Xin-Xin Liu
Zhi-Yuan Qiu
Lan-Ping Xu
Xiao-Hui Zhang
Yu Wang
Chen-Hua Yan
Huan Chen
Yu-Hong Chen
Wei Han
Feng-Rong Wang
Jing-Zhi Wang
Si-Ning Liu
Kai-Yan Liu
Xiao-Jun Huang
Xiao-Dong Mo
Source :
Therapeutic Advances in Hematology, Vol 13 (2022)
Publication Year :
2022
Publisher :
SAGE Publishing, 2022.

Abstract

Purpose: Graft- versus -host disease (GVHD) is an important complication after human leukocyte antigen (HLA) haploidentical donor (HID) hematopoietic stem cell transplantation (HSCT), which may lead to poor prognosis. Our study intends to identify the efficacy and safety of mesenchymal stem cells (MSCs) for multidrug-resistant (MDR)-GVHD after HID HSCT. Methods: MDR-GVHD was referring to GVHD remaining no response to at least two types of therapy, and hUCB-MSCs were given at the dose of (1.0–2.0) × 10 6 /kg once a week. Results: A total of 21 patients were enrolled in this retrospective study (acute GVHD (aGVHD): n = 14, chronic GVHD (cGVHD): n = 7). The median dose of MSCs was 1.2 × 10 6 cells/kg (range, 0.8–1.8 × 10 6 ) cells/kg, and the median numbers of infusion were 2 (range, 1–7) and 3 (range, 2–12) for MDR-aGVHD and MDR-cGVHD patients, respectively. In MDR-aGVHD patients, the overall response rate (ORR) was 57.1%, including 50.0% complete response (CR) and 7.1% partial response (PR), and the median time to response was 49.5 days (range, 16–118) days. The 2-year probability of overall survival after MSCs was 64.3%. Five patients (35.7%) developed infections after MSCs, and no obvious hematologic toxicities were observed. Five MDR-aGVHD patients died after MSCs treatments because of GVHD progression ( n = 1), severe infection (bacterial central nervous system infection: n = 1; fungal pneumonia: n = 2), and poor graft function ( n = 1). In MDR-cGVHD patients, three patients (42.9%) achieved PR after MSCs and the median time to response was 56 days (22–84) days. The ORRs for moderate and severe cGVHD were 50.0% and 33.3%, respectively. Four MDR-cGVHD patients died after MSCs treatments because of GVHD progression ( n = 2), severe fungal pneumonia ( n = 1), and relapse ( n = 1). Conclusion: MSCs treatment may be safe and effective for MDR-GVHD after HID HSCT.

Details

Language :
English
ISSN :
20406215 and 20406207
Volume :
13
Database :
Directory of Open Access Journals
Journal :
Therapeutic Advances in Hematology
Publication Type :
Academic Journal
Accession number :
edsdoj.44771582a1ed44e18367d168931f1ad5
Document Type :
article
Full Text :
https://doi.org/10.1177/20406207211072838